Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
- Written by PR Newswire
SHANGHAI, June 5, 2025 /PRNewswire/ -- At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUC)...
Read more: Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO